Recursion Merges with Exscientia to Accelerate Drug Discovery
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
- Latest
- Trending
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
Read about Germany's stock market dip as DAX, MDAX, and TecDAX indices fall. Highlights include top gainers and losers across ...
Pharmaceutical giants Bristol Myers Squibb and Johnson & Johnson invest in Accent Therapeutics, a leading RNA drug developer, contributing to ...
Activist investors are expected to launch more campaigns for change in European companies, following a record number in 2023. Europe ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.